Skip to main content
Premium Trial:

Request an Annual Quote

Erytech Pharma, MD Anderson Ink Companion Dx Deal

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – French firm Erytech Pharma today said that it will collaborate with MD Anderson Cancer Center in Houston on the development of a companion diagnostic for the firm's anticancer drug candidate.

The companion diagnostic would be used to determine which patients would be most likely to respond to the company's Graspa therapy, which consists of red blood cell-encapsulated L-asparaginase (L-ASP). The drug is already used in leukemia chemotherapy regimens, but Erytech also is developing it for treatment of solid tumors.

John Weinstein, chair of the department of bioinformatics and computational biology at MD Anderson, said that researchers at the center have identified a candidate biomarker, asparagine synthetase, that may predict L-ASP activity against solid tumors.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.